Top Blue Chip Stocks To Buy Right Now

U.K. stocks on Wednesday wavered, with the International Monetary Fund set to offer its assessment of the British economy, but blue chips remained close to a six-week high.

London-listed shares were lower alongside other global markets, which were unable to gain much traction after U.S. lawmakers made a major push forward into overhauling the country’s tax code.

How markets are moving: The FTSE 100 index
UKX, -0.13%
was up 1 point at 7,545.46 after dipping into negative territory. The basic materials and health care groups were gaining the most, but consumer goods and utilities were among the sector that fell. On Tuesday, the index rose 0.1% and marked it best close since Nov. 6.

Top Blue Chip Stocks To Buy Right Now: Arrow Electronics, Inc.(ARW)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Arrow Electronics (ARW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribing]

    Arrow Electronics (NYSE:ARW) Q4 2018 Earnings Conference CallFeb. 7, 2019 1:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Lee Jackson]

    This award-winning company looks poised to come in strong for the quarter. Arrow Electronics Inc. (NYSE: ARW) is a worldwide provider of products, services and solutions to industrial and commercial users of electronic components and enterprise computing solutions.

  • [By Ethan Ryder]

    PNC Financial Services Group Inc. increased its holdings in Arrow Electronics, Inc. (NYSE:ARW) by 29.7% in the first quarter, HoldingsChannel.com reports. The firm owned 19,225 shares of the technology company’s stock after buying an additional 4,405 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Arrow Electronics were worth $1,480,000 at the end of the most recent reporting period.

Top Blue Chip Stocks To Buy Right Now: Kitov Pharamceuticals Holdings Ltd.(KTOV)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    TransEnterix, Inc. (NYSE: TRXC) rose 28.8 percent to $4.03 in pre-market trading after the company disclosed that it has received the FDA clearance for expanded indications for its Senhance Surgical System.
    Global Eagle Entertainment Inc. (NASDAQ: ENT) rose 15.6 percent to $2.30 in pre-market trading.
    Companhia Brasileira de Distribuição (NYSE: CBD) rose 13.2 percent to $24.20 in pre-market trading.
    ZTO Express (Cayman) Inc. (NYSE: ZTO) rose 12.2 percent to $21.65 in pre-market trading. Alibaba and Cainiao agreed to make strategic investment in ZTO Express of $1.38 billion.
    DHI Group, Inc. (NYSE: DHX) rose 10.8 percent to $2.05 in pre-market trading.
    Momo Inc. (NASDAQ: MOMO) shares rose 9.6 percent to $42.68 in pre-market trading after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares rose 9.1 percent to $6.00 in pre-market trading.
    Universal Display Corporation (NASDAQ: OLED) rose 8.4 percent to $108.00 in pre-market trading.
    Jupai Holdings Limited (NYSE: JP) shares rose 7 percent to $24.50 in pre-market trading after reporting Q1 results.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 5.9 percent to $10.61 in pre-market trading.
    Frontline Ltd. (NYSE: FRO) rose 5.9 percent to $5.04 in pre-market trading.
    Evogene Ltd. (NASDAQ: EVGN) rose 5.5 percent to $3.27 in pre-market trading after reporting Q1 results.
    Sears Holdings Corporation (NASDAQ: SHLD) rose 5.5 percent to $3.68 in pre-market trading after gaining 5.44 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) shares rose 5.4 percent to $2.16 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Lisa Levin]

    Kitov Pharma Ltd (NASDAQ: KTOV) shares dropped 17 percent to $2.53. Kitov Pharma priced its 3.26 million ADS offering at $2.50 per ADS.

    Shares of Ambow Education Holding Ltd. (NASDAQ: AMBO) were down 26 percent to $4.1999.

  • [By Lisa Levin]

    Kitov Pharma Ltd (NASDAQ: KTOV) shares dropped 16 percent to $2.56. Kitov Pharma priced its 3.26 million ADS offering at $2.50 per ADS.

    Shares of Ambow Education Holding Ltd. (NASDAQ: GLNG) were down 28 percent to $4.10.

Top Blue Chip Stocks To Buy Right Now: Brink's Company (BCO)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday.
    Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86.
    J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings.
    Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory.
    Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results.
    The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c
  • [By Max Byerly]

    Shares of Brink’s (NYSE:BCO) have earned a consensus rating of “Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $99.50.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Brink’s (BCO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Blue Chip Stocks To Buy Right Now: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Jim Crumly]

    As for individual stocks, Boeing (NYSE:BA) slumped due to trade concerns, and Sarepta Therapeutics (NASDAQ:SRPT) soared following positive trial results.

  • [By Todd Campbell]

    Investors cheered news that PTC Therapeutics’ (NASDAQ:PTCT) clinical-stage drug for spinal muscular atrophy (SMA) is delivering impressive early-stage efficacy. However, those cheers turned to jeers after competitor Sarepta Therapeutics (NASDAQ:SRPT) reported promising data for its Duchenne muscular dystrophy (DMD) gene therapy. Could Sarepta Therapeutics’ next-generation DMD treatment derail sales of PTC Therapeutics’ existing DMD drugs? And how excited should investors be about PTC Therapeutics’ opportunity to reshape SMA treatment anyway?

  • [By Keith Speights]

    Three biotech stocks — Solid Biosciences (NASDAQ:SLDB), Sarepta Therapeutics (NASDAQ:SRPT), and Heron Therapeutics (NASDAQ:HRTX) — soared this week by 30% or more thanks to news that brought smiles to investors’ faces. Here’s what drove these stocks higher and whether or not they’re smart picks to buy now.

  • [By Keith Speights]

    Three gene therapy stocks aren’t just hot in 2018 — they’re red-hot. Shares of  Sarepta Therapeutics (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), and uniQure (NASDAQ:QURE) have nearly doubled or generated even greater gains so far this year. But is it too late for investors to buy these gene therapy stocks? Here’s what you need to know.

  • [By Max Byerly]

    Royal Bank of Canada restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Wednesday morning, MarketBeat reports. The firm currently has a $200.00 target price on the biotechnology company’s stock, up from their previous target price of $187.00.

Leave a Reply

Your email address will not be published. Required fields are marked *